Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13954125 | 0.77 | CTSS (0.36) | CTSSMMP2MMP3MMP1PKM | |
| SCHEMBL14898392 | 0.74 | CTSS (0.38) | CTSSMMP2MMP3MMP1PKM | |
| SCHEMBL19790147 | 0.74 | CTSS (0.38) | CTSSMMP2MMP3MMP1PKM | |
| SCHEMBL23845057 | 0.70 | DPP4 (0.42) | — | |
| SCHEMBL18117423 | 0.68 | — | — | |
| SCHEMBL12509930 | 0.68 | — | — | |
| SCHEMBL14027140 | 0.67 | SIGMAR1 (0.55) | CTSSPKM | |
| SCHEMBL14725189 | 0.66 | — | — | |
| SCHEMBL15499751 | 0.66 | — | — | |
| SCHEMBL15095619 | 0.66 | ESR1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360483-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | IPSEN PHARMA S.A.S. (FR) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360483-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | PROKR1, CCL2, PROKR2 | CTSS 1530/4885MMP2 359/4885MMP3 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.